Meillä on vahvaa toimialaosaamista ja kokemusta sekä terveydenhuollossa että lääke- ja terveysteknologiassa. Olemme toimineet menestyksellisesti ja pitkään sekä kotimaisten että ulkomaisten toimijoiden juridisena neuvonantajana.
Avustamme asiakkaitamme muun muassa seuraavilla alueilla: terveydenhuoltopalvelut, terveydenhuollon koneet ja laitteet, lääkkeet, julkiset hankinnat ja niihin liittyvät riitaisuudet, tutkimussopimukset, elintarvikesääntely, IPR-riidat ja tietosuoja.
Autamme asiakkaitamme kaupallistamaan keksintöjä, suojelemaan keskeisiä immateriaalioikeuksia ja jäsentämään liiketoimintaa ja kumppanuuksia siten, että markkinoille saadaan nopeasti ja helposti seuraavan sukupolven lääkkeitä, tuotteita ja palveluita.
Our Life Sciences and Healthcare capability in Ireland
Ireland generates an enormous output in the life sciences sector, from the world’s largest corporates to a vibrant indigenous community. Ireland is home to 14 of the world’s top 15 Medical Technology companies and 9 of the top 10 Pharma companies. With offices in Dublin and Belfast, we present you with an all-island, cross-departmental, full legal service offering. Our life sciences team are able to help you with a range of intellectual property licensing to product liability, from regulatory advices to navigating the local healthcare ecosystem. Our cross-disciplinary team can advise you at all phases of development and has experience in every aspect of the life sciences sector.
Our recent experience includes advising:
- an Irish medical device manufacturer which is a world leader in nebulizer technology on its arrangements with one of Chinas largest life sciences enterprises for the deployment of the clients’ proprietary nebulizer technology for the use in the inhaled delivery of a Covid-19 vaccine
- a locally-based manufacturer of surgical wound closure devices in connection the clinical trial process for its latest devices. The clinical trials were conducted in a number of medical institutions across a number of EU jurisdictions
- a clinical diagnostics client on its most recent fundraising including an award of significant European Union Funding for development and commercialization of its rapid testing products for use in respect of detecting presence of the Covid-19 virus
- members of a multimember US specialized Private Equity Group on a significant Series B Investment Round in an Irish based device manufacturing enterprise. The investment round involved investment by strategic investment funds and industry participants from across the globe
- a major international generic drug manufacturer on its local establishment including the construction of its European Manufacturing Headquarters and business transfer to the new faciltity
Yhteyshenkilöt
Uusimmat Artikkelit
- legal updatesThe EDPB’s new scientific research guidelines: a welcome route map, but no shortcut for “research” by assertion
- legal updatesHong Kong: Open consultation on listing reforms
- legal updatesEU Legislation Roundup: February 2026
- legal updatesHow statutory warranty laws differ across jurisdictions
Uusimmat Uutiset
- toimistomme uutisetEversheds Sutherland Advises The Centurion Foundation on Completed Acquisition of Roger Williams Medical Center and Fatima Hospital
- asiakasuutisetEversheds Sutherland advises on £5.2bn disposal of Barchester Healthcare
- asiakasuutisetEversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
- toimistomme uutisetEversheds Sutherland continues IP and Life Sciences practice expansion with European lateral partner hire
legal updates
28. huhtikuuta 2026
The EDPB’s new scientific research guidelines: a welcome route map, but no ...
legal updates
14. huhtikuuta 2026
Hong Kong: Open consultation on listing reforms
legal updates
05. maaliskuuta 2026
EU Legislation Roundup: February 2026
legal updates
02. maaliskuuta 2026
How statutory warranty laws differ across jurisdictions
toimistomme uutiset
20. maaliskuuta 2026
Eversheds Sutherland Advises The Centurion Foundation on Completed Acquisit...
asiakasuutiset
06. marraskuuta 2025
Eversheds Sutherland advises on £5.2bn disposal of Barchester Healthcare
asiakasuutiset
06. syyskuuta 2024
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of C...
toimistomme uutiset
03. marraskuuta 2022
Eversheds Sutherland continues IP and Life Sciences practice expansion with...